Free shipping on all orders over $ 500

Toceranib phosphate

Cat. No. M20877
Toceranib phosphate Structure


Size Price Availability
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Toceranib phosphate is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.

Chemical Information
Molecular Weight 494.45
Formula C22H28FN4O6P
CAS Number 874819-74-6
Solubility (25°C) DMSO 2 mg/mL
Water 2 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Sabina Sheppard-Olivares, et al. Vet Rec Open. Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019)

[2] Petros Frezoulis, et al. Vet Comp Oncol. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review

[3] Hiroki Yamazaki, et al. J Vet Intern Med. Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs

[4] Felicia H Lew, et al. Vet Comp Oncol. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018

[5] C London, et al. Vet Comp Oncol. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours

Related VEGFR/PDGFR Products

Pegdinetanib (BMS-844203; CT-322) is a selective VEGFR-2 (VEGFR) inhibitor with Kds of 11 nM and 250 nM and IC50s of 16 nM and 240 nM for human and murine VEGFR-2, respectively. Pegdinetanib does not bind to VEGFR-1 or VEGFR-3. Pegdinetanib has antitumor activity.


Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats.


Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers.


Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

Efdamrofusp alfa

Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions.

Abmole Inhibitor Catalog

Keywords: Toceranib phosphate, SU11654 supplier, VEGFR/PDGFR, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.